Sphere Fluidics, a Cambridge, UK-based life science company, closed a £1.6m funding round.
Among others, backers include a syndicate of London Business Angels and its EIS Approved Roundtable Syndicate Fund 2012.
The company intends to use the funding to expand its management resources, relocate to a new facility and accelerate sales growth.
Led by CEO, Frank Craig, Sphere Fluidics is commercializing an innovative single cell analysis technology which can accelerate new bio-pharmaceutical discovery, generate stem cell therapies and enable novel studies on single cell diseases such as cancer.
This picodroplet technology has already been used by a number of Blue Chip clients.